Redeye updates its estimates and valuation after Indutrade’s Q2 2025 report. Larger-than-expected organic headwinds led to both top and bottom-line misses versus our projections. While we judge headline figures looked worse than underlying fundamentals suggest, Indutrade’s organic recovery proceeds more slowly than we pencilled in. Still, we believe the company will realise solid operating leverage once demand turns around.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/